Curocell Statistics
Total Valuation
Curocell has a market cap or net worth of KRW 383.87 billion. The enterprise value is 409.39 billion.
Market Cap | 383.87B |
Enterprise Value | 409.39B |
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025.
Earnings Date | May 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Curocell has 14.32 million shares outstanding.
Current Share Class | 14.32M |
Shares Outstanding | 14.32M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | +0.25% |
Owned by Insiders (%) | 33.64% |
Owned by Institutions (%) | 10.55% |
Float | 9.44M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 13.03 |
P/TBV Ratio | 13.72 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -10.71 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -14.18 |
Financial Position
The company has a current ratio of 0.34, with a Debt / Equity ratio of 1.27.
Current Ratio | 0.34 |
Quick Ratio | 0.30 |
Debt / Equity | 1.27 |
Debt / EBITDA | n/a |
Debt / FCF | -1.29 |
Interest Coverage | -14.07 |
Financial Efficiency
Return on equity (ROE) is -86.36% and return on invested capital (ROIC) is -27.13%.
Return on Equity (ROE) | -86.36% |
Return on Assets (ROA) | -25.87% |
Return on Invested Capital (ROIC) | -27.13% |
Return on Capital Employed (ROCE) | -110.08% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.33% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -16.33% |
50-Day Moving Average | 27,628.00 |
200-Day Moving Average | 28,871.90 |
Relative Strength Index (RSI) | 48.24 |
Average Volume (20 Days) | 24,414 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | -10.49M |
Operating Income | -36.62B |
Pretax Income | -38.24B |
Net Income | -38.24B |
EBITDA | -30.29B |
EBIT | -36.62B |
Earnings Per Share (EPS) | -2,736.20 |
Balance Sheet
The company has 11.78 billion in cash and 37.30 billion in debt, giving a net cash position of -25.52 billion or -1,781.64 per share.
Cash & Cash Equivalents | 11.78B |
Total Debt | 37.30B |
Net Cash | -25.52B |
Net Cash Per Share | -1,781.64 |
Equity (Book Value) | 29.45B |
Book Value Per Share | 2,074.34 |
Working Capital | -25.70B |
Cash Flow
In the last 12 months, operating cash flow was -28.42 billion and capital expenditures -441.02 million, giving a free cash flow of -28.86 billion.
Operating Cash Flow | -28.42B |
Capital Expenditures | -441.02M |
Free Cash Flow | -28.86B |
FCF Per Share | -2,015.06 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Curocell does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -9.96% |
FCF Yield | -7.52% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |